Aurobindo Pharma Shares Surge Post Q3 Results, Street Awaits Management Commentary

• Aurobindo Pharma shares opened higher after reporting Q3 earnings largely ahead of estimates, with margins in line.
• Net profit rose 7.5% YoY to ₹909.8 crore, slightly below CNBC-TV18 poll but impacted by a ₹65 crore labor code charge.
• Revenue increased 8.4% YoY to ₹8,646 crore, comfortably beating street estimates.
• EBITDA grew 12.4% YoY to ₹1,773.6 crore, with operating margins at 20.5%.
• Growth was driven by strong performance in Europe (+27% YoY) and the ARV segment (+22.5% YoY); US business also exceeded estimates.